LENSAR, Inc. Price & Performance (LNSR)

Alcon has entered a definitive agreement to acquire LENSAR, Inc. for $14 per share in cash, with an additional contingent value right of up to $2.75 per share, bringing the potential deal value to $430 million. The acquisition aims to strengthen Alcon’s femtosecond laser-assisted cataract surgery offerings, pending regulatory and shareholder approval.123

LENSAR shares recently closed at $13.49, falling short of Alcon’s $14 per share acquisition offer. The stock has experienced volatility and downward pressure, with analysts maintaining a hold rating. Investors appear cautious, possibly reflecting uncertainty around deal completion or contingent value right milestones.456

Under the merger agreement, LENSAR shareholders will receive $14 per share in cash and a contingent value right worth up to $2.75, dependent on procedure milestones. This structure provides both immediate liquidity and potential future upside, but also introduces risk tied to achieving specific operational targets post-acquisition.278